Breaking News Instant updates and real-time market news.

CATB

Catabasis Pharmaceuticals

$1.83

0.07 (3.98%)

, SRPT

Sarepta

$46.60

2.26 (5.10%)

08:31
09/28/17
09/28
08:31
09/28/17
08:31

Catabasis to present results from Sarepta collaboration at ICWMS

Catabasis Pharmaceuticals (CATB) said it will present data from the Catabasis and Sarepta (SRPT) joint research collaboration in Duchenne muscular dystrophy at the 22nd International Congress of the World Muscle Society in a poster presentation titled "Edasalonexent, an NF-kB inhibitor, enhances myotube formation in vitro, and increases exon-skipped sarcolemmal dystrophin in muscle of mdx mice" during poster session 4 on Thursday, October 5, 2017 from 17:00 - 18:30 CEST. The International Congress of the World Muscle Society is being held October 3 - 7, 2017, at the Palais du Grand Large in Saint Malo, France.

CATB

Catabasis Pharmaceuticals

$1.83

0.07 (3.98%)

SRPT

Sarepta

$46.60

2.26 (5.10%)

CATB Catabasis Pharmaceuticals
$1.83

0.07 (3.98%)

03/17/17
OPCO
03/17/17
NO CHANGE
Target $11
OPCO
Outperform
Oppenheimer remains bullish on Catabasis Pharmaceuticals
Oppenheimer analyst Hartaj Singh remains bullish on Catabasis Pharmaceuticals after quarterly results. The analyst notes that the company is hvaing an eventful 2017 with edasalonexent not meeting its primary and secondary endpoints in Part B of the MoveDMD clinical trial. However, a potential efficacy signal was noted and the focus on the earnings call was Part C of the MoveDMD trial, he argues, adding that he is "cautiously optimistic" that long-term treatment in Part C may show enough of an efficacy signal for the drug to move forward into further clinical trials. Singh reiterates an Outperform rating and $11 price target on the shares.
06/21/17
WEDB
06/21/17
NO CHANGE
WEDB
Sentiment towards Catabasis Pharmaceuticals improving, says Wedbush
Wedbush analyst Liana Moussatos says recent comments by investors indicate that sentiment towards Catabasis Pharmaceuticals is improving. The analyst notes that the stock dropped sharply after the company's drug missed its primary endpoint in a study in January. However, she says that investors are starting to put more emphasis on "the totality of the company's data," and beginning to look forward to 24 week Part C results in Q3. The analyst adds that the company's drug edasalonexent when combined with exon-skipping treatment has shown signs of boosting dystrophin production, while its CAT-5571 appears to have "positively affected a cystic fibrosis disease process in an experimental cell model." She keeps a $4 price target and an Outperform rating on the stock.
08/14/17
HCWC
08/14/17
NO CHANGE
Target $9
HCWC
Buy
Catabasis Pharmaceuticals price target raised to $9 from $8 at H.C. Wainwright
H.C. Wainwright analyst Carol Ann Werther raised her price target for Catabasis Pharmaceuticals to $9 and keeps a Buy rating on the shares. The MoveDMD trial Part C data, expected in Q3, is required to move edasalonexent into pivotal trials, the analyst tells investors in a research note. She expects to see a numerical improvement in multiple functional assessments, which "may be sufficient" to guide the design of the pivotal trial and move the program forward.
08/14/17
OPCO
08/14/17
NO CHANGE
Target $4
OPCO
Outperform
Catabasis Pharmaceuticals price target lowered to $4 from $9 at Oppenheimer
Oppenheimer analyst Hartaj Singh lowered his price target for Catabasis Pharmaceuticals to $4 from $9 as a comprehensive Phase 3 program potentially pushes out sales timelines and reduces sales potential. The analyst reiterates an Outperform rating on the shares.
SRPT Sarepta
$46.60

2.26 (5.10%)

09/07/17
OPCO
09/07/17
NO CHANGE
Target $76
OPCO
Outperform
Data removes another overhang on Sarepta, says Oppenheimer
Oppenheimer analyst Hartaj Singh notes that Sarepta provided an update on its 4053-101 study, a two-part study designed to assess the safety, tolerability and pharmacokinetics of four dose levels of SRP-4053 and an open-label evaluation of SRP-4053 in patients with deletions amenable to exon 53 skipping. The positive result removes an overhang on Sarepta, he contends, as some investors had posited that weak biopsy results from 4053-101 could reignite the Exondys 51 approval controversy from 2H16. The analyst reiterates an Outperform rating and $76 price target on the shares.
09/15/17
RBCM
09/15/17
INITIATION
RBCM
Outperform
Sarepta initiated on positive catalysts at RBC Capital
As noted earlier, RBC Capital started coverage of Sarepta with a $64 price target and an Outperform rating. Analyst Matt Eckler identified the company as one of his top small/mid-cap biotech picks. The analyst says that the commercial opportunity of the company's Exondys 51 is greater than the market believes, while the company's pipeline is "underappreciated" and it has other potential catalysts.
09/25/17
JPMS
09/25/17
NO CHANGE
JPMS
Neutral
JPMorgan 'somewhat cautious' on PTC into FDA panel meeting
JPMorgan analyst Anupam Rama says he remains "somewhat cautious" on shares of PTC Therapeutics (PTCT) with the FDA's Peripheral and Central Nervous Systems Drugs Advisory Committee convening on September 28 to review the company's Translarna for the treatment of non-sense mutation Duchenne muscular dystrophy. Translarna has an FDA action date of October 24. The analyst cites the drug's "mixed" Phase 2 and Phase 3 datasets and prior refuse-to-file letter for his "somewhat cautious" stance. For Sarepta Therapeutics (SRPT), Rama sees a net positive read-through from a favorable panel, on the potential for an accelerated path forward for golodirsen in Exon 53 DMD. Further, a negative panel is likely to be viewed as Translarna-specific, playing out as a net neutral for Sarepta, the analyst tells investors in a research note. He does not see "major fundamental downside risk" for Sarepta shares going into PTC's panel. Rama keeps a Neutral rating on PTC and Overweight rating on Sarepta.
09/27/17
LEER
09/27/17
NO CHANGE
LEER
Outperform
Sarepta doesn't see read through from PTC AdComm, says Leerink
After hosting Sarepta (SRPT) executives, Leerink analyst Joseph Schwartz noted management stated they do not anticipate any read through to Sarepta's exon skipping drugs from the advisory committee meeting to discuss PTC Therapeutics' (PTCT) ataluren as the therapies have different mechanisms and address different disease states. Additionally, the company said Exondys 51's U.S. launch has exceeded expectations, sales outside the U.S. are expected to be slower than U.S. sales, that they see a potential FDA filing for golodirsen in Q1 of 2018 and that they will update guidance in 2018. Schwartz keeps an Outperform rating on Sarepta shares.

TODAY'S FREE FLY STORIES

HLF

Herbalife

$83.29

0.35 (0.42%)

15:19
02/22/18
02/22
15:19
02/22/18
15:19
Options
Herbalife options imply 11.1% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

BLK

BlackRock

$540.70

-2.86 (-0.53%)

, RGR

Sturm, Ruger

$48.75

1.45 (3.07%)

15:17
02/22/18
02/22
15:17
02/22/18
15:17
Periodicals
BlackRock to speak with gun makers, distributors after FL shooting, Reuters says »

BlackRock (BLK) said it…

BLK

BlackRock

$540.70

-2.86 (-0.53%)

RGR

Sturm, Ruger

$48.75

1.45 (3.07%)

AOBC

American Outdoor Brands

$10.06

-0.12 (-1.18%)

WMT

Walmart

$92.78

1.26 (1.38%)

DKS

Dick's Sporting

$32.94

0.1 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 18

    Mar

  • 23

    Apr

$NSD

NASDAQ Market Internals

15:17
02/22/18
02/22
15:17
02/22/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GTLS

Chart Industries

$49.71

-0.26 (-0.52%)

15:16
02/22/18
02/22
15:16
02/22/18
15:16
Upgrade
Chart Industries rating change  »

Chart Industries upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 14

    Mar

$NYE

NYSE Market Internals

15:16
02/22/18
02/22
15:16
02/22/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:15
02/22/18
02/22
15:15
02/22/18
15:15
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

15:15
02/22/18
02/22
15:15
02/22/18
15:15
General news
Breaking General news story  »

Dallas Federal Reserve…

BLK

BlackRock

$542.19

-1.37 (-0.25%)

15:10
02/22/18
02/22
15:10
02/22/18
15:10
Periodicals
BlackRock plans to engage with gun makers, sellers, Bloomberg says »

BlackRock, one of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 25

    Feb

  • 01

    Mar

  • 06

    Mar

  • 07

    Mar

  • 23

    Apr

FSLR

First Solar

$66.70

0.12 (0.18%)

15:04
02/22/18
02/22
15:04
02/22/18
15:04
Options
First Solar options imply 12.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 15

    Mar

XLF

Financial Select Sector

$28.85

-0.079 (-0.27%)

, XLV

Health Care Select Sector SPDR

$84.25

0.13 (0.15%)

15:03
02/22/18
02/22
15:03
02/22/18
15:03
Technical Analysis
Technical Take: S&P 500 falls to session lows heading into last hour of trading »

The S&P 500 (SPX) was…

XLF

Financial Select Sector

$28.85

-0.079 (-0.27%)

XLV

Health Care Select Sector SPDR

$84.25

0.13 (0.15%)

XRT

S&P Retail Index SPDR

$45.41

0.07 (0.15%)

SPY

SPDR S&P 500 ETF Trust

$271.15

1.1 (0.41%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASFI

Asta Funding

$10.60

0.7 (7.07%)

15:02
02/22/18
02/22
15:02
02/22/18
15:02
Hot Stocks
Asta Funding announces receipt of Nasdaq non-compliance letter »

Asta Funding announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$166.36

1.44 (0.87%)

14:59
02/22/18
02/22
14:59
02/22/18
14:59
Periodicals
Massachusetts officials say Wynn investigation a priority, Bloomberg says »

Officials from the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NNN

National Retail Properties

$37.99

0.93 (2.51%)

14:58
02/22/18
02/22
14:58
02/22/18
14:58
Syndicate
Breaking Syndicate news story on National Retail Properties »

National Retail…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTRI

Nutrisystem

$41.10

-0.2 (-0.48%)

14:50
02/22/18
02/22
14:50
02/22/18
14:50
Options
Healthy put spread in NutriSystems ahead of earnings »

Healthy put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

OLED

Universal Display

$155.60

-5.5 (-3.41%)

14:49
02/22/18
02/22
14:49
02/22/18
14:49
Options
Universal Display options imply 12.2% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

AMD

AMD

$11.72

-0.3 (-2.50%)

14:40
02/22/18
02/22
14:40
02/22/18
14:40
Options
AMD put volume tops 100K contracts »

AMD put volume tops 100K…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

MIC

Macquarie Infrastructure

$37.98

-25.64 (-40.30%)

14:30
02/22/18
02/22
14:30
02/22/18
14:30
Hot Stocks
Macquarie Infrastructure plunges after cutting dividend »

Shares of Macquarie…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

14:30
02/22/18
02/22
14:30
02/22/18
14:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY was…

PEG

PSEG

$49.26

0.73 (1.50%)

, COG

Cabot Oil & Gas

$24.07

0.82 (3.53%)

14:28
02/22/18
02/22
14:28
02/22/18
14:28
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PEG

PSEG

$49.26

0.73 (1.50%)

COG

Cabot Oil & Gas

$24.07

0.82 (3.53%)

HUN

Huntsman

$33.50

-0.09 (-0.27%)

CNK

Cinemark

$39.95

0.33 (0.83%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Feb

  • 23

    Feb

  • 26

    Feb

  • 28

    Feb

  • 05

    Mar

  • 23

    May

INTU

Intuit

$173.32

-0.25 (-0.14%)

, HPQ

HP Inc.

$21.41

0.24 (1.13%)

14:27
02/22/18
02/22
14:27
02/22/18
14:27
Earnings
Notable companies reporting after market close »

Notable companies…

INTU

Intuit

$173.32

-0.25 (-0.14%)

HPQ

HP Inc.

$21.41

0.24 (1.13%)

HPE

HP Enterprise

$16.40

0.145 (0.89%)

BMRN

BioMarin

$84.21

0.36 (0.43%)

GDDY

GoDaddy

$55.13

-0.57 (-1.02%)

OLED

Universal Display

$155.60

-5.5 (-3.41%)

HLF

Herbalife

$83.42

0.48 (0.58%)

FSLR

First Solar

$66.70

0.12 (0.18%)

EXAS

Exact Sciences

$46.64

-1.37 (-2.85%)

PLNT

Planet Fitness

$33.17

-0.51 (-1.51%)

TTD

Trade Desk

$49.81

-0.39 (-0.78%)

WING

Wingstop

$45.73

1.7 (3.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 26

    Feb

  • 26

    Feb

  • 28

    Feb

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 15

    Mar

  • 22

    Mar

  • 28

    Mar

  • 24

    Apr

  • 25

    May

  • 30

    May

  • 12

    Sep

14:25
02/22/18
02/22
14:25
02/22/18
14:25
General news
NASDAQ comp briefly rolled over into the red »

NASDAQ comp briefly…

TGNA

Tegna

$13.73

-0.26 (-1.86%)

14:17
02/22/18
02/22
14:17
02/22/18
14:17
Hot Stocks
TEGNA names Howard Elias non-executive chairman of the board »

TEGNA announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

  • 05

    Mar

$NSD

NASDAQ Market Internals

14:17
02/22/18
02/22
14:17
02/22/18
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
02/22/18
02/22
14:16
02/22/18
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:10
02/22/18
02/22
14:10
02/22/18
14:10
General news
Fed Policy Outlook: the release of the text of the Monetary Policy Report »

Fed Policy Outlook: the…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.